Dennis Dean: Hey, thanks, Josh. Yes, from a rate perspective, if you kind of look through the quarters, you’ll see there’s a lot of variability with our rate, it bounces from quarter-to-quarter, couple of reasons for that, obviously, acuity and the types of procedures, the case mix and those types of things. We can’t really control who walks in the door. Obviously, as you know, but that’s a component of it. And then we did take some promotional activities in the fourth quarter that did bring the rate down a touch there from what we had sort of forecasted. We had projected, sort of, to be in our high-end of our sort of projected range of $12,000 to $13,000 as you see that we came in on the low-end of that. And obviously that did give us a little bit of revenue shortfall from a rate perspective as well. And you know our conversion metrics within EBITDA are so high that little bit of rate did impact us from an EBITDA standpoint for sure.
Aaron Rollins: Josh, it’s Aaron Rollins. I also want to let you know that we did do a lot of promotion in the fourth quarter and we did it, because the data showed it worked. And it definitely drove case volume. What we’re going to do this year that’s a little bit different is we’re working on different ways to promote to actually drive ASP such as bundling and giving patient more value, but for a higher price point.
Josh Raskin: Okay. Got you, got you. And then second question just on the guidance for EBITDA, overall margin sounds like relative be flat in 2023. I heard margin expansion maybe in the second-half, so maybe there’s a little compression in the first-half. But can we just revisit that, sort of, variable cost versus fixed cost base and why we shouldn’t expect more of the revenue growth to translate into EBITDA margin expansion?
Dennis Dean: Sure. Just — I’ll, kind of, hit the variable component first. When you look at it from an EBITDA standpoint, about 53% of our costs are variable. So we still have a very high variable component. Obviously, the physicians and supplies would be the number ones there, as well as is our advertising numbers. But some of the expansion Josh is really related to us taking a more measured approach in our rates. Again, as I spoke of previously in the question, we have such a profitable profile on our revenue that we took a little more measured response in how we looked at rate going into next year. We think of $12,000 to $13,000 is kind of our range and we took a midpoint, which obviously is a little bit lower than where we finished out in 2022.
But I think it’s opportunity for us there and clearly because of the profitability aspect of it, it’s not giving us as much EBITDA margin expansion as you would probably expect. And, you know, Todd talked about the cost structure and the management of that, obviously whenever you start looking at a lot of things across the board, it takes a while and so that’s why we’re sort of assessing in the back half of the year of the impact there. And we think we’ll probably get a couple million in year for that potentially we think on a run rate basis we’re looking close to $5 million, so we’re really taking a deep, deep dive into that.
Josh Raskin: Okay. Thank you.
Operator: Thank you. Our next question comes from the line of Korinne Wolfmeyer with Piper Sandler. Please proceed with your question.
Korinne Wolfmeyer: Hey, good morning, all. Thanks for taking the question and Todd, it’s great to finally talk to you. I guess first question, kind of, bouncing off of that margin question. Could you just expand a little bit on what we should expecting for gross margins going forward? I mean, it did take a pretty heavy step down in ’22? Is that kind of the proper run rate we should be looking at going forward? Or what kind of expansion could we seen there?